Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

PIONEER

In this page

Clinical Trial

NCT03326336 Recruiting, Active
PIONEER

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in SubjectsWith Retinitis Pigmentosa (PIONEER).

Phase 3
Interventional

Disease

Disease type

Retinitis Pigmentosa

Orphan drug recognition

No

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

23/01/2018

Closing date

01/05/2024

Inclusion criteria :

More

Exclusion criteria :

More

Funding

industry

Members involved

Main investigators

Dr Elise Boulanger-Scemana

France

See more

Others investigators

Dr Jean-François Girmens

France

See more

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

ERN EYE member investigating site

HCP : Principal investigators